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Steady-state pharmacokinetics of delavirdine 
in HIV-positive patients: Effect on 
erythromycin breath test 
Objective: The steady-state kinetics of delavirdine and desisopropyldelavirdine were evaluated in human 
immunodeficiency virus-positive patients after escalating oral doses and after repeated oral administra- 
tions at the same dose level. 
Study den&: Patients (B = 8 males) were given escalating oral doses of delavirdine mesylate, in a sequential 
fashion, over 14 days for phases l(200 mg every 8 hours), 2 (300 mg every 8 hours), and 3 (400 mg every 
S hours). Control patients (n = 4 males) were given 300 mg oral doses of drug every 8 hours for all three 
phases. Hepatic CYP3A activity was evaluated with the erythromycin breath test (ERMBT). 
Restilts: In the escalating-dose group, delavirdine displayed nonlinear kinetics as indicated by the decreas- 
ing oral clearance, maximum steady-state plasma concentration/minimum steady-state plasma concentra- 
tion ratio, and log-linear terminal rate constant, as well as by the increasing half-life at higher doses; the 
ratio of desisopropyl-delavirdine formation clearance to elimination clearance was also reduced. In the 
control group, the kinetics of delavirdine and desisopropyl-delavirdine were unchanged. Plasma protein 
binding was linear for delavirdine in the escalating-dose and control groups; on average, the fraction 
unbound was about 2.3% and 2.0%, respectively. Hepatic CYP3A activity was markedly reduced after 
short- and long-term exposure to all doses of delavirdine mesylate. Delavirdine could maximally inhibit 
70% to 75% of predose ERMBT values, with an IC50 of about 0.9 pmol/L. 
Conclusion: Delavirdine is a potent and reversible inhibitor of hepatic CYP3A, it is also a substrate for this 
CYP450 isoform. It is likely that delavirdine will exhibit drug-drug interactions when coadministered 
with other CYP3A substrates. (Clin Pharmacol Ther 1997;61:531-43.) 
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The bisheteroarylpiperazines (BHAPs) are a class 
of non-nucleoside compounds that have been shown 
to inhibit the reverse transcriptase of human immu- 
nodeficiency virus (HIV) type 1 (HIV-l) and to 
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block HIV-l replication in cell culture.1-6 These 
compounds are highly specific inhibitors of HIV-l 
reverse transcriptase (RT), having no activity 
against the RT of HIV-2 or the other animal retro- 
viruses.5’6 As a member of this class of compounds, 
delavirdine acts exclusively as a mixed inhibitor of 
both the RNA- and DNA-directed DNA polymer- 
ase domains of the RT enzyme.7 In this capacity, 
delavirdine has a much higher binding affinity for 
the enzyme-substrate complex than for the free en- 
zyme and, as a result, it does not directly impair the 
function of the substrate binding site. 
During clinical development, it was observed that 
delavirdine had a nonlinear disposition in human 
subjects, so that single-dose kinetics could not be 
used to accurately predict the steady-state plasma 
concentrations of drug.8P9 However, these studies 
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Table I. Demographic data for HIV-positive patients 
Group1 Body 
Patient gender1 Age weight Smoker 
No. race 0 (kg) status 
8 
9 
10 
11 
12 
Mean 
SD 
m4m7 
l/M/w 
2/M/w 
mm7 
l/M/W 
l/M/B 
l/M/w 
l/M/B 
l/M/w 
m4m 
1MIB 
1IMIw 
28 118 f 299 52 
31 60.2 2 339 38 
24 65.9 + 81 26 
2.5 67.4 + 571 36 
36 69.1 ” 259 61 
35 66.8 +- 329 67 
43 73.6 + 27 133 
38 75.0 -I- 130 35 
31 101 + 10 115 
33 90.0 zt 259 35 
32 62.8 -t 4 35 
32 70.9 - 271 32 
32 76.7 215 55 
5 17.4 170 34 
2 
23 
35 
56 
89 
92 
36 
145 
36 
26 
24 
53 
37 
4.6 19 1.2 
4.6 12 1.1 
4.4 22 1.2 
4.8 9 0.9 
4.3 9 0.8 
3.6 11 0.7 
3.7 7 0.7 
4.0 9 1.0 
3.9 13 0.8 
4.3 13 1.0 
3.9 16 0.9 
3.9 13 1.1 
4.2 13 1.0 
0.4 4 0.2 
M, Male; B, black; W, white; +, active smoker; f, previous smoker; -, nonsmoker; CD4, initial T-lymphocyte cell count; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; ALB, serum albumin; BUN, blood urea nitrogen; SCR, serum creatinine. 
were performed using different subjects for each 
dose level, thus complicating the interpretation of 
pharmacokinetic data among treatment groups. 
More importantly, the data offered no insight into 
the mechanism of dose-dependent kinetics. In vitro 
studies in liver microsomes from several animal spe- 
cies (including human) have shown that the major 
metabolic pathway of delavirdine is N-deal$lation, 
a process catalyzed primarily by cytochrome P450 
3A (CYP3A) isoforms.” Further, it appears that 
delavirdine may inhibit CYP3A through a 
mechanism-based process. As a result, it is possible 
that the in vivo clearance of delavirdine may be 
attenuated as a consequence of capacity-limited ki- 
netics, as well as by diminished enzymatic capacity. 
With this in mind, the objectives of the proposed 
study were (1) to define the steady-state pharmaco- 
kinetics of delavirdine and its N-desisopropyl me- 
tabolite in HIV-positive patients after escalating 
oral doses and after repeated oral administrations at 
the same dose level, (2) to determine the in vivo 
effect of delavirdine mesylate on CYP3A activity in 
liver, and (3) to establish the relationship between 
hepatic CYP3A activity in vivo and delavirdine 
plasma concentrations. 
METHODS 
Patientpopulation. Patients with written documen- 
tation of HIV-l infection were enrolled in the study. 
Patients ranged in age from 24 to 43 years, in body 
weight from 60.2 to 118 kg, and in initial CD4 counts 
from 4 to 571 cells/mm3. Nine of the patients were 
white and three of the patients were black. Six pa- 
tients were active smokers, five were previous smok- 
ers, and one patient was a nonsmoker. None of the 
patients had acute medical problems or histories of 
clinically significant disease (e.g., renal, hepatic, car- 
diovascular, gastrointestinal, or neurologic). In ad- 
dition, patients were not taking any drugs known to 
be enzyme inducers or inhibitors.” The most com- 
monly coadministered medications were acetamin- 
ophen (paracetamol; five patients), trimethoprim- 
sulfamethoxazole (five patients), zidovudine (four 
patients), dapsone (three patients), ibuprofen (two 
patients) and acyclovir (aciclovir; two patients). In- 
dividual demographic data are provided in Table I. 
All study protocols were approved by the Institu- 
tional Review Board of the University of Michigan 
Medical School, and written consent was obtained 
from each patient. 
Study design. The protocol for this study specified 
an open-label, parallel-group, multiple-dose phar- 
macokinetic study in adult HIV-positive male or 
female patients. Patients in group 1 (n = 8 males) 
were given escalating oral doses of delavirdine me- 
sylate, in a sequential fashion, for phases 1,2, and 3. 
In phase 1, patients were given 200 mg delavirdine 
mesylate (two 100 mg tablets) every 8 hours for 14 
days. On day 15, a full pharmacokinetic study was 
performed immediately after the morning dose. In 
phase 2, patients were given 300 mg delavirdine 
mesylate (three 100 mg tablets) every 8 hours for 14 
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days (days 17 through 30), and on day 31 a full 
pharmacokinetic study was performed after the 
morning dose. In phase 3, patients were given 400 
mg delavirdine mesylate (four 100 mg tablets) every 
8 hours for 14 days (days 33 through 46), and on day 
47 a full pharmacokinetic study was performed after 
the first dose. Patients in group 2 (n = 4 males) were 
given 300 mg oral doses of delavirdine mesylate 
(three 100 mg tablets) every 8 hours for all three 
phases. 
On days 15 and 31 (the first two pharmacokinetic 
assessments), serial blood samples (3 ml) were ob- 
tained at time 0 (predose) and at %, %, ?%, 1, l%, 2, 
2%, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 48 hours after 
dosing. For the 1, 2, 4, 6, and 8 hour postdose 
samples, an additional 5 ml blood sample was ob- 
tained for protein binding determinations. On day 
47 (the third pharmacokinetic assessment), serial 
blood samples were obtained as described above, 
with an additional sample taken at 72 hours after 
dosing. Blood volumes were also obtained for pro- 
tein binding determinations as described above. 
Trough plasma concentrations (3 ml blood samples) 
were monitored on designated days during the 54- 
day study period. Blood was drawn from a forearm 
vein, by venipuncture or an indwelling catheter, into 
heparin-containing Vacutainer tubes (3 ml samples) 
or ethylenediaminetetraacetic acid-containing Va- 
cutainer tubes (5 ml samples). Blood samples were 
centrifuged immediately and the plasma was har- 
vested. After the plasma was heated for 30 minutes 
at 56” C (except in those samples for protein binding 
determinations), samples were frozen I -20” C. 
Patients were admitted to the General Clinical 
Research Center on the nights before pharmacoki- 
netic assessments and were not allowed to eat or 
drink anything (except water) at least 6 hours before 
dosing. Two hours after delavirdine was adminis- 
tered, patients were given 6 ounces of orange juice. 
A standardized lunch and dinner was provided 4 and 
10 hours after dosing, and all beverages were decaf- 
feinated. 
Erythromycin breath test. Several erythromycin 
breath tests were performed in each patient to as- 
sess the temporal and drug-related effects on 
CYP3A activity in the liver and the resultant effects 
on delavirdine kinetics. The erythromycin breath 
test (ERMBT) was performed just before the start 
of the delavirdine study (day 1) and during drug 
administration on the mornings of days 2 and 14 
(i.e., 24 hours after initiating the first dose rate and 
at steady state for phase l), days 18 and 30 (i.e., 24 
hours after initiating the second dose rate and at 
steady state for phase 2), days 34 and 46 (i.e., 24 
hours after initiating the third dose rate and at 
steady state for phase 3) and after washout from 
the last previous dose (day 50 or 54 or both). 
Each patient received the ERMBT a total of 8 to 9 
times, as described previously.12,13 In brief, patients 
were given 3 l&i (CO.1 pmol) of [r4C-N- 
methyllerythromycin intravenously while at rest, and 
breath samples were collected before and 20 min- 
utes after injection. The expired r4C02 was mea- 
sured by liquid scintillation counting. Breath test 
results are expressed as the percent of administered 
14C exhaled during the first hour after injection of 
erythromycin, as estimated by a single breath collec- 
tion obtained at 20 minutes. 
Heidelberg capsules. Delavirdine is a weakly basic 
amine (pKa = 4.5) that may exhibit dissolution- 
limited absorption because of its poor aqueous sol- 
ubility at elevated pH values.* Moreover, the de- 
creased gastric acid secretion observed in some 
patients with acquired immunodeficiency syndrome 
(AIDS) could result in poor or erratic oral drug 
performance.14 With this is mind, gastric pH was 
monitored on the days that pharmacokinetic assess- 
ments were performed (i.e., days 15,31, and 47) with 
the Heidelberg capsule, a nondigestible radiotele- 
metric indicator of gastrointestinal pH.15,16 In brief, 
at approximately 30 minutes before drug dosing, the 
Heidelberg capsule, tethered to a string, was posi- 
tioned in the stomach with the aid of 90 ml water. Its 
position was verified by fluoroscopy after the first 
treatment (day 15) and by the measured length of 
tether for subsequent treatments. The oral delavir- 
dine dose was then administered with 8 ounces of 
water, and continuous radiotelemetric measure- 
ments were made for an additional 4 hours (for a 
total of 4% hours). After these measurements, the 
capsule was retrieved orally. 
Analytical procedures. Delavirdine (MW 456.6) 
and its N-desisopropyl metabolite (MW 414.5) were 
quantitated simultaneously in human plasma with 
use of a sensitive and specific HPLC assay with 
fluorescence detection.r7 Calibration curves were 
constructed over a low plasma concentration range 
(25 to 5000 rig/ml) and over a high plasma concen- 
tration range (100 to 25,000 @ml). Quality control 
samples (50, 100, 400, 800, 4000, and 20,000 @ml) 
“Investigator brochure for delavirdine mesylate: a non- 
nucleoside reverse transcriptase inhibitor. Pharmacia & Up- 
john Inc., Kalamazoo, Mich., July 1995. 
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Phase 1 Phase 2 Phase 3 Phase 1 Phase 2 Phase 3 
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Fig. 1. Plasma concentration-time profiles for delavir- 
dine (A) and desisopropyl-delavirdine (B) in the 
escalating-dose group of HIV-positive patients (group 1). 
Data reported as mean values + SE (n = 7). 
were run for drug and metabolite over a 5day pe- 
riod. Overall, the precision (% coefficient of varia- 
tion [%CV]) and accuracy (% bias) of the assay 
were ~9.7% and ~9.2%, respectively. 
For those samples that contained dapsone, the 
assay was modified to separate delavirdine desiso- 
otn-nnl-nnlll 
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A Time (hr) 
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Fig. 2. Plasma concentration-time profiles for delavir- 
dine (A) and desisopropyl-delavirdine (B) in the control 
group of HIV-positive patients (group 2). Data reported 
as mean values k SE (n = 4). 
propyl metabolite, dapsone, and dapsone mono- 
acetyl metabolite. Minor modifications included a 
change in the mobile phase to 10 mmol/L monobasic 
potassium phosphate (pH 6.0)/acetonitrile/metha- 
no1 (20:7:7) and a reduction in the volume of buffer 
(from 400 to 300 t.~l) mixed with supernatant solu- 
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Table II. Delavirdine pharmacokinetics after oral dosing of delavirdine mesylate at 200 mg every 8 hours 
(day 15, phase l), 300 mg every 8 hours (day 31, phase 2), and 400 mg every 8 hours (day 47, phase 3) 
Parameters Day 1.5 Day 31 Day 47 Friedman’s test 
CL/F (L/hr) 14.5 t 17.6 
CE (wnol/L) 5.56 ? 2.89 
Cgi, (pmol/L) 1.98 k 1.20 
CZi, (kmol/L) 12.6 ? 6.70 
t,, @4 0.93 + 0.28 
Cf&/C~, ratio 8.42 k 5.29 
A, (hr-‘) 0.277 k 0.053 
b2 (hr) 2.59 + 0.53 
CL,,/CL,,, ratio 0.401 5 0.293 
fu (%I 2.29 ?I 0.31 
7.85 t 6.07 
11.1 ? 4.011 
5.79 i. 2.52? 
18.8 + 7.23* 
1.37 t 0.78* 
3.77 2 1.65.f 
0.222 + 0.065* 
3.33 t 0.89* 
0.244 ? 0.1271 
2.38 2 0.33 
7.79 IT 5.95 
17.0 k 8.717 
10.1 t 5.41-t 
26.6 + 12.9.f 
2.23 + 1.69* 
2.75 t 0.90? 
0.188 t 0.064-f 
4.12 5 1.52-t 
0.197 ? 0.106Jr 
2.33 -c 0.32 
p = 0.0498 
p = 0.0021 
p = 0.0021 
p = 0.0058 
p = 0.0361 
p = 0.0038 
p = 0.0119 
p = 0.0119 
p = 0.0021 
p = 0.3679 
Data are reported as mean values I SD (n = 7). 
*p 5 0.10, tp 5 0.05 when day 31 or day 47 is compared with day 15 (Wilcoxon signed-rank test using Bonferroni-adjustedp values). 
CL/F, Oral clearance; C& average steady-state plasma concentration; Czi,, minimum steady-state plasma concentration; C&., maximum steady-state plasma 
concentration; t,,, time to reach C,,; A,, log-linear terminal rate constant; t1,2, half-life; CL,,, metabolite formation clearance; CL,,,, metabolite 
elimination clearance; f,, fraction unbound. 
Table III. Desisopropyl-delavirdine pharmacokinetics after oral dosing of delavirdine mesylate at 200 mg 
every 8 hours (day 15, phase l), 300 mg every 8 hours (day 31, phase 2) and 400 mg every 8 hours (day 47, 
phase 3) 
Parameters Day 15 Day 31 Day 47 Friedman’s test 
(2% (pmol/L) 
Cgin ( pmol/L) 
CE, (pmol/L) 
t,, W 
CgJCz, ratio 
A, (hr-‘) 
tl12 (W 
1.57 -+- 0.36 2.34 2 0.593- 2.69 + 0.89t p = 0.0021 
0.946 t 0.333 1.79 k 0.627 2.15 2 0.73-t p = 0.0038 
2.18 t 0.41 2.88 -c 0.60* 3.23 2 0.98.f p = 0.0119 
1.68 -c 0.55 1.84 t 1.60 3.59 i- 2.57 p = 0.5073 
2.63 2 1.16 1.69 ? 0.31-f 1.54 + 0.22* p = 0.0211 
0.158 + 0.043 0.121 ? 0.032* 0.101 + 0.032.f p = 0.0058 
4.71 ? 1.51 6.18 + 1.98* 7.50 i- 2.44? p = 0.0058 
Data are reported as mean values 2 SD (n = 7). 
*p c 0.10, tp 5 0.05 when day 31 or day 47 is compared with day 15 (Wilcoxon signed-rank test using Bonferroni-adjustedp values). 
tion from extracted plasma. Under these conditions, 
dapsone (2.1 minutes) and dapsone monoacetyl me- 
tabolite (2.4 minutes) were eluted first, followed by 
delavirdine desisopropyl metabolite (2.7 minutes), 
the internal standard U-88,822 (6.6 minutes) and 
delavirdine (7.3 minutes). Quality control samples 
(40,400, 4000, and 20,000 rig/ml) were run for drug 
and metabolite over a 1Cday period. Overall, the 
precision (%CV) and accuracy (% bias) of the assay 
were ~4.3% and <8.8%, respectively. 
Protein binding. The in vivo binding of delavirdine 
to plasma proteins was determined with use of ra- 
diolabeled drug and an equilibrium dialysis method. 
The radiolabel was prepared as 14C-delavirdine me- 
sylate, with a specific activity of 44.4 tKi/mg and 
radiochemical purity >99% (lot No. 27792-EHD- 
38D). Samples were prepared by adding 10 ul ra- 
diolabeled drug (after appropriate dilution with 
methanol) to 1.0 ml plasma so that counts were 
obtained in the region of 55,000 dpm/ml. Plasma 
samples and isotonic phosphate buffer (0.067 mol/L, 
pH 7.4) were preequilibrated to 37” C before loading, 
and 0.75 ml plasma was then dialyzed against an equal 
volume of buffer for 6 hours at 37” C with Spectrapor 
2 membrane tubing. Radioactive measurements for 
14C-drug were performed on a liquid scintillation 
counter after mixing 200 ~1 dialyzed plasma or buffer 
with 5 ml scintillation fluid. An external standard 
method was used for quench correction, with a count- 
ing time of 10 minutes or <2% error. 
Data analysis. Pharmacokinetic parameters were 
calculated for delavirdine and its N-desisopropyl 
metabolite with use of a noncompartmental ap- 
proach. r8 The half-life (t,,, = 0.693/X,) was deter- 
mined by linear regression with use of at least four 
data points from the log-linear terminal phase of the 
curve; h, is the log-linear terminal rate constant. The 
steady-state area under the plasma concentration- 
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Table IV. Delavirdine pharmacokinetics after oral dosing of delavirdine mesylate at 300 mg every 8 hours 
(day 15, phase l), 300 mg every 8 hours (day 31, phase 2), and 300 mg every 8 hours (day 47, phase 3) 
Parameters Day 15 Day 31 Day 47 Friedman’s test 
9.44 +- 5.39 
8.63 + 3.50 
4.95 k 2.08 
15.2 r 5.3 
1.25 t 0.84 
3.21 t 0.46 
0.210 t 0.048 
3.47 c 0.97 
0.276 " 0.056 
2.14 + 0.50 
8.06 k 1.77 
8.75 + 2.00 
4.88 + 1.64 
14.6 + 1.4 
0.93 + 0.42 
3.18 2 0.73 
0.200 L 0.023 
3.51 2 0.45 
0.266 + 0.069 
2.04 + 0.55 
6.73 + 2.00 
10.7 2 2.9 
6.55 + 2.23 
18.4 5 6.7 
1.13 2 0.75 
2.82 2 0.30 
0.199 2 0.053 
3.66 + 0.95 
0.226 2 0.074 
1.90 + 0.52 
p = 0.7788 
p = 0.7788 
p = 0.4724 
p = 0.7788 
p = 0.6456 
p = 0.4724 
p = 0.7788 
p = 0.7788 
p = 0.1738 
p = 0.0183 
Data are reported as mean values 2 SD (n = 4). 
*p 5 0.10, tp 5 0.05 when day 31 or day 47 is compared with day 15 (Wiicoxon signed-rank test using Bonferroni-adjustedp values). 
Table V. Desisopropyl-delavirdine pharmacokinetics after oral dosing of delavirdine mesylate at 300 mg 
every 8 hours (day 15, phase l), 300 mg every 8 hours (day 31, phase 2), and 300 mg every 8 hours (day 47, 
phase 3) 
Parameters Day 15 Day 31 Day 47 Friedman’s test 
CE (wWL) 
Czin (wol/L) 
G&Py'iz' 
C&JC& ratio 
X, (hr-‘) 
b2 W 
2.31 + 0.98 2.32 + 0.73 2.27 t 0.27 p = 0.7788 
1.85 2 0.78 1.80 + 0.59 1.72 t 0.24 p = 0.7788 
2.87 1 63 2 t 0.75 1 08 2.77 1 62 2 rf: 0.86 47 2.86 1 50 2 t 0.52 1 15 p = 0.3679 9394
1.59 + 0.19 1.55 5 0.14 1.67 t 0.13 p = 0.7788 
0.0957 + 0.0227 0.110 + 0.010 0.100 t 0.024 p = 0.3679 
7.54 5 1.66 6.32 + 0.59 7.19 t 1.60 p = 0.3679 
Data are reported as mean values + SD (n = 4). 
*p 5 0.01, tp 5 0.05 when day 31 or day 47 is compared with day 15 (Wilcoxon signed-rank test using Bonferroni-adjustedp values). 
time curve (AUCF) was determined over the dosing 
interval, r (i.e., from time zero to 8 hours), with use of 
a combination of the trapezoidal and log-trapezoidal 
rules. The average steady-state plasma concentration 
was then calculated as follows: Cat = AUCF/r. The 
minimum (C$J and maximum (CE3 plasma con- 
centrations and the time to reach the maximum con- 
centration (~3 were determined by visual inspection 
of the data. Fluctuation ratio was then calculated as 
Flue = CEJCzti. The oral clearance of delavirdine 
was calculated as CL/F = D/AUCTS, in which D is the 
oral delavirdine dose, CL is the total plasma clearance, 
and F is the fraction of administered dose systemically 
available. The ratio of desisopropyl-delavirdine forma- 
tion clearance to elimination clearance was deter- 
m&l as CJGorm/CLmet = AUC~~desisopropyl-delavirdine)/ 
AUC”” T (delavirdiie)* 
Protein binding analyses were performed on plasma 
samples from pharmacokinetic assessment days (i.e., 
days 15, 31, and 47) at 1, 2, 4, 6, and 8 hours after 
dosing. No evidence of nonlinear plasma protein bind- 
ing was observed for delavirdine in any of the samples 
tested. Therefore its unbound fraction (expressed as 
percentage) was determined as follows: 
f,(%) = 100 * Cf’/(Cf’ + Cb’) 
in which Cf’ is the unbound concentration of drug in 
buffer after dialysis, and Cb” is the volume-corrected 
bound concentration of drug in the postdialysis plas- 
ma.19 In a given treatment, the unbound fraction for 
each patient represents the mean of four to five 
determinations. 
The relationship between ERMBT values and 
delavirdine plasma concentration (C) was analyzed 
for each patient with use of a modified E,, model: 
E/E, = 100 - I,, . C/(IC,, + C) 
in which E, is the baseline effect for ERMBT in the 
absence of drug, E/E, is the observed effect for 
ERMBT in the presence of drug (expressed as a 
percent of control), I,, is the maximum inhibitory 
effect on ERMBT caused by the drug (expressed as 
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a percent of inhibition), and IC,, is the delavirdine 
concentration (expressed as pmol/L) that produces 
50% of the maximum inhibitory effect. Unknown 
parameters (I,, and IC,,) were obtained with use 
of the nonlinear least-squares regression program 
Scientist for Windows version 2.0 (MicroMath Sci- 
entific Software, Salt Lake City, Utah), with a 
weighting factor of unity. 
Data are reported as mean values t SD unless 
otherwise indicated. For each parameter, statistical 
differences were determined between treatments (or 
phases) by Friedman’s test, followed by the Wil- 
coxon signed-rank test using Bonferroni-adjusted 
p values. All statistical computations were per- 
formed with SYSTAT version 5.2 (Systat Inc., Evan- 
ston, Ill.). 
RESULTS 
Pharmacokinetics. Plasma concentrations ob- 
tained during the 0- to S-hour dosing interval on 
pharmacokinetic assessment days (i.e., days 15, 31, 
and 47) represent steady-state values for delavirdine 
and its N-desisopropyl metabolite (Figs. 1 and 2). In 
the escalating-dose group, delavirdine displayed 
nonlinear kinetics as indicated by the decreasing 
CL/F, C~,/C~, ratio, and X,, as well as by the 
mcreasmg tliz at higher doses (Table II). It also 
appears that the N-desisopropyl metabolite was pro- 
duced at reduced levels relative to the amount of 
delavirdine present in plasma. Thus, at higher doses 
the ratio of desisopropyl-delavirdine formation 
clearance to elimination clearance (CL,,,/CL,,,) 
was significantly reduced, suggesting a saturable 
metabolic pathway for delavirdine N-dealkylation. 
Protein binding of delavirdine was not dose depen- 
dent, and the fraction unbound averaged about 
2.3% for each treatment. The desisopropyl metab- 
olite of delavirdine also displayed nonlinear kinetics, 
as indicated by its decreasing C~ax/CsIsin and h, and 
by its increasing t,,, at higher doses (Table III). 
Patient 9 was excluded from these analyses because 
of noncompliance with the study protocol. 
In the control group, the kinetics of delavirdine and 
desisopropyl-delavirdine were unchanged after re- 
peated administrations of the same dose during three 
different phases of multiple-drug dosing (Tables IV 
and V, respectively). Thus it appears that, on average, 
the kinetics of 300 mg delavirdine mesylate (given 
orally three times a day) were reproducible over this 
time period. However, there was one exception. In this 
regard, the fraction unbound for delavirdine was sta- 
tistically dilferent over the three different phases. This 
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Fig. 3. Relationship between the erythromycin breath 
test (ERMBT) and time for patient 5 (escalating-dose 
group; A) and patient 10 (control group; B). Samples were 
obtained before dosing and 1 and 13 days after initiation 
of each of the three treatment phases. A, Escalating-dose 
group: phase 1, 200 mg every 8 hours; phase 2, 300 mg 
every 8 hours; phase 3, 400 mg every 8 hours. B, Control 
group: phase 1, 300 mg every 8 hours; phase 2, 300 mg 
every 8 hours; phase 3, 300 mg every 8 hours. 
change was considered to be unimportant in that its 
reduction over time was on the order of only 11% and 
the change was not reflective of nonlinear plasma 
protein binding (compare with Table II). 
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Fig. 4. Relationship between the ERMBT and delavirdine plasma concentrations with use of 
pooled data. The solid line represents the computer-simulated curve based on mean values for 
the fitted parameters in Table VI. 
Table VI. Parameter estimates for inhibition of the erythromycin breath test (ERMBT) by delavirdine 
plasma concentrations 
Patient Predose ERMBT 
No. (70 14C exhaledlhr) 
I mar 
(TO inhibition) ? 
1 3.31 85.3 (7.1) 1.49 (0.50) 
2 4.53 80.9 (1.6) 0.370 (0.056) 
3 4.83 76.7 (2.0) 0.0538 (0.0124) 
4 1.69 67.8 (11.4) 2.96 (1.74) 
5 3.91 76.5 (2.0) 0.626 (0.064) 
6 2.43 71.8 (2.8) 0.825 (0.215) 
7 1.66 62.6 (2.0) 0.463 (0.142) 
8 3.09 76.3 (14.9) 0.360 (0.218) 
9 2.31 64.3 (6.2) 0.128 (0,044) 
10 1.99 73.0(3.8) 0.753 (0.285) 
11 2.48 77.5 (11.2) 1.80 (0.83) 
12 1.80 67.5 (1.4) 0.832(0.119) 
Mean + SD 2.84 !I 1.10 73.3 i. 6.8 0.889 + 0.831 
See text for model. 
Values in parentheses represent the standard deviation of individual parameter estimates. P is the coefficient of determination. 
0.9048 
0.9581 
0.9326 
0.5802 
0.9794 
0.8872 
0.8212 
0.7767 
0.8332 
0.7368 
0.9057 
0.9614 
- 
ERMBT. Exposure to oral doses of delavirdine ples depicted in Fig. 3. As observed for patient 5 
mesylate resulted in a rapid and substantial reduc- (Fig. 3, A; escalating-dose group), there was a 
tion in CYP3A activity in the liver for all patients. monotonic decline in hepatic CYP3A activity as 
This is clearly shown by the representative exam- larger doses of drug were administered and as 
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duration of drug administration increased from 1 
to 14 days. In a similar fashion, hepatic CYP3A 
activity was reduced for patient 10 (Fig. 3, B; 
control group) after delavirdine administration, 
with the effect being greater at steady state than 
after 1 day of dosing. After washout from the 
body, ERMBT measurements returned to their 
predose values within 3 days, indicating that inhi- 
bition of hepatic CYP3A was rapidly and com- 
pletely reversible. 
As shown in Table VI, I,, and IC,, could be 
estimated reasonably well in each of the 12 pa- 
tients. On average, the predose value for ERMBT 
was 2.84, with 70% to 75% being maximally in- 
hibited by delavirdine, which had an IC,, of about 
0.9 pmol/L. A large intersubject variability was 
also observed in some of the parameter estimates. 
Thus the variability, expressed by %CV and 
range, was 38.7% (2.9-fold range) for predose 
ERMBT, 9.3% (1.4-fold range) for I,,, and 
93.5% (55.0-fold range) for IC5,,. Although there 
was little variability in the maximum inhibitory 
effect of delavirdine, variability in the sensitivity 
to drug (i.e., IC,,) was substantial. The overall 
relationship between ERMBT and delavirdine 
plasma concentrations is displayed in Fig. 4 with 
use of pooled data. Patient 9 was included in this 
analysis because assurance of steady-state levels 
was not a requirement. 
A significant positive correlation was observed 
between ERMBT and the logarithm of the 
desisopropyl-delavirdine/delavirdine plasma con- 
centration ratios with pooled data (Fig. 5; r = 
0.7908; p < O.OOOl), showing that delavirdine is also 
a substrate for hepatic CYP3A. An even stronger 
correlation was observed when comparisons were 
made in individual patients (mean + SD; r = 
0.9253 2 0.0635; y1 = 12). Thus, as hepatic CYP3A 
activity was reduced (as indicated by the smaller 
values for ERMBT), less desisopropyl metabolite 
was formed relative to a given concentration of 
delavirdine. 
Heidelberg capsules. Group 1 (escalating-dose) 
and group 2 (control) patients had gastric pH 
values that were between 1 and 2 for all three 
phases (Fig. 6; phase 1 data shown). The pH was 
somewhat elevated after the oral dose of delavir- 
dine given with 8 ounces of water, and after the 
ingestion of 6 ounces of orange juice given 2 hours 
after dosing. These effects were of short duration, 
with pH values returning to baseline in about l/2 
hour. In contrast, patient 11 had a substantially 
0 
0 
Y 
0 1 I I 
0.1 1 10 
Desisopropyl-delavirdine/Delavirdine 
Fig. 5. Linear correlation between the ERMBT and 
the logarithm of desisopropyl-delavirdine:delavirdine 
plasma concentration ratios using pooled data. Confi- 
dence intervals (95%) have been added to the regres- 
sion line. 
elevated pH versus time profile for all three 
phases of drug administration. This particular pa- 
tient had gastric pH values that were generally 
between 4 and 6 for the first 2 hours after the 
dose. After ingesting 6 ounces of orange juice, his 
pH dropped to values consistent with groups 1 
and 2. Nevertheless, the kinetic parameters of 
patient 11 were not unusual compared with other 
patients in the escalating-dose group or compared 
with the control group after the 300 mg dose. Patient 
9 was not included in these analyses because correct 
positioning of the Heidelberg capsule was inadver- 
tently not verified by fluoroscopy and, as a result, the 
data were considered to be unreliable. 
Safety. Delavirdine was well tolerated under the 
conditions of this study, with no serious medical 
events reported. The most frequently reported 
events were rash (43%) and headache (36%). Pa- 
tients completing the study received the drug 
through the rash with the exception of one patient 
requiring treatment with hydroxyzine. All but one 
instance of rash had resolved by the end of the 
study. The remaining rash resolved within 2 weeks 
of the end of the study. 
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Fig. 6. Gastric pH versus time profiles for patients in the escalating-dose group (n = 6; 
diamonds), the control group (n = 4; circles) and patient 11 (triangles} during the phase 1 
treatment. Group data are reported as mean values + SE. 
DISCUSSION 
Delavirdine has been shown to have nonlinear phar- 
macokinetics in human subjects.* In an escalating 
multiple-dose study in healthy volunteers (daily oral 
doses of 60 to 400 mg), there was a 15fold decrease 
in delavirdine oral clearance, a threefold increase in 
half-life, and a fivefold decrease in the ratio of 
N-desisopropyl metabolite formation clearance to me- 
tabolite elimination clearance over the dose range 
studied.’ A similar trend was observed during escalat- 
ing multiple doses in HIV-positive patients.’ However, 
these studies were performed in parallel, with different 
patients participating at each dose level. In the present 
multiple-dose crossover study, delavirdine was esca- 
lated over a more limited range (i.e., daily oral doses of 
600,900, and 1200 mg). Under these conditions, there 
was considerable between- and within-subject variabil- 
ity in delavirdine kinetics, as illustrated in Fig. 7. Still, 
the oral clearance of delavirdine was observed to de- 
crease by about 45% at the larger dose rates (Table II). 
*Investigator brochure for delavirdine mesylate: a non- 
nucleoside reverse transcriptase inhibitor. Pharmacia & Up- 
john Inc., Kalamazoo, Mich., July 1995. 
Because delavirdine was administered only by the oral 
route, its reduced oral clearance may reflect either a 
decrease in total plasma clearance, an increase in sys- 
temic availability, or both. 
Support for a decrease in the total plasma clear- 
ance of delavirdine was afforded by several obser- 
vations. First, the CL,,,/CL,,, ratio was reduced 
by about 40% to 50% at the larger dose rates 
(Table II). Thus, as the daily dose of delavirdine 
increased, the N-dealkylated metabolite of dela- 
virdine was formed less efficiently relative to the 
amount of delavirdine present in the systemic 
circulation. Second, the delavirdine half-life in- 
creased by about 30% to 60% as the dose rate 
increased, yet the drug’s apparent volume of dis- 
tribution was unchanged [VJF = (CL/F)&: 
phase 1, 49.5 L; phase 2, 33.0 L; phase 3; 39.5 L; 
p = 0.65141. Third, hepatic CYP3A activity, as- 
sessed directly by the ERMBT, was shown to be 
inhibited by delavirdine (Table VI and Fig. 3). 
Changes in systemic availability alone would not 
account for the combined alterations in delavir- 
dine’s oral clearance, CL,,,/CL,,,, and half-life. 
However, increased drug levels as a consequence 
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Fig. 7. Relationship between delavirdine steady-state area under the plasma concentration- 
time curve AUCP versus dose (A) and delavirdine maximum steady-state plasma concentra- 
tion Cg, versus dose (B) for the escalating-dose (group 1) and control (group 2) patients. 
of more drug being absorbed or less drug being 
removed by presystemic metabolism in the gut and 
liver could cause a subsequent effect on the total 
plasma clearance of delavirdine. As a result, the po- 
tential for a dose-dependent increase in delavirdine’s 
bioavailabihty cannot be ruled out at the present time. 
Nonlinear kinetics were observed in the 
escalating-dose group for the desisopropyl metabo- 
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lite of delavirdine, as noted previously (Table III). 
Although the reason for a dose-dependent half-life 
of desisopropyl-delavirdine is unclear at present, it 
is possible that another delavirdine metabolite (e.g., 
hydroxydelavirdine) is competing for the same met- 
abolic pathway (e.g., sulfation). Further, the longer 
half-life of desisopropyl-delavirdine, compared with 
parent drug, suggests that the plasma decay of this 
metabolite is rate limited by its own elimination. 
As observed in Fig. 4, delavirdine exposure re- 
sulted in a rapid and potent decrease in hepatic 
CYP3A activity, reaching a maximum inhibitory ef- 
fect at delavirdine plasma concentrations of about 5 
ymol/L or greater. Because the average steady-state 
levels of delavirdine in all treatment groups were >5 
pmol/L on average, oral doses of 200, 300, or 400 
mg delavirdine (given three times a day) are suffi- 
cient to produce a potent inhibition of CYP3A in 
liver. The maximal inhibitory effect of delavirdine 
was estimated at 70% to 75%. The other 25% to 
30% of metabolic activity not affected by delavirdine 
probably represents extrahepatic CYP3A and addi- 
tional CYP450 isoforms in the liver or elsewhere. 
In summary, the following conclusions can be 
made from this study: (1) the steady-state kinetics of 
delavirdine and desisopropyl-delavirdine remained 
unchanged after repeated oral administrations of 
drug at the same dose level, (2) the steady-state 
kinetics of delavirdine and desisopropyl-delavirdine 
were nonlinear after escalating oral doses of dela- 
virdine mesylate, (3) delavirdine (or its metabolites) 
is a potent and reversible inhibitor of CYP3A in 
liver, (4) the I,, of delavirdine is 70% to 75% and 
its IC,,, is about 0.9 pmol/L, (5) CYP3A represents 
a major pathway for delavirdine N-dealkylation in 
vivo, and (6) delavirdine will probably exhibit drug- 
drug interactions when coadministered with other 
CYP3A substrates. 
Delavirdine mesylate (100 mg oral tablets) and radio- 
labeled delavirdine mesylate were provided by Pharmacia 
& Upjohn, Inc. (Kalamazoo, Mich.). We thank Rachel 
Henegar and Cynthia Vansteenburg for their help with 
the clinical aspects of the study. 
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